Moderna looks outside US for growth
Digest more
Moderna reported falling fourth-quarter sales as Covid-19 vaccine demand continued to drop, but continues to target 10% ...
Moderna (NASDAQ: MRNA) reported fourth-quarter results Friday morning that beat Wall Street’s muted expectations, delivering ...
In 2025, Moderna spent $3.1 billion on R&D, a 31% decrease from the $4.5 billion budget (PDF) in 2024 and a further drop from ...
Signed Memorandum of Understanding supports "Plan Mexico," Mexico's strategic initiative to build a local mRNA ...
Drug observers puzzled by vaccine maker, which made a killing on COVID-19, failing to read the room with new administration. Moderna puts heat on FDA vaccines chief who's already been rebuked once by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results